Free Trial
David Lebowitz

David Lebowitz Analyst Performance

Senior Research Analyst at Citigroup

David Lebowitz is a stock analyst at Citigroup in the medical sector, covering 14 publicly traded companies. Over the past year, David Lebowitz has issued 24 stock ratings, including buy, hold, and sell recommendations. While full access to David Lebowitz's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights David Lebowitz's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
24 Last 0 Years
Buy Recommendations
66.67% 16 Buy Ratings
Companies Covered
14 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy66.7%16 ratings
Hold29.2%7 ratings
Sell4.2%1 ratings

Out of 24 total stock ratings issued by David Lebowitz at Citigroup, the majority (66.7%) have been Buy recommendations, followed by 29.2% Hold and 4.2% Sell.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
14 companies

David Lebowitz, an analyst at Citigroup, currently covers 14 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
14 companies
100.0%

David Lebowitz of Citigroup specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
11 companies
78.6%
MED - DRUGS
1 company
7.1%
MEDICAL INFO SYS
1 company
7.1%
MED - GENERIC DRG
1 company
7.1%

About David Lebowitz

David Lebowitz currently works at Citigroup Global Markets, Inc. (Broker), as Senior Research Analyst from 2021. Mr. Lebowitz also formerly worked at Piper Sandler & Co. (Broker), as Research Analyst from 2013 to 2014, Morgan Stanley & Co. LLC, as Equity Analyst from 2015 to 2021, Summit Technology, Inc., as Regulatory Specialist in 1999, SMH Capital, Inc. (Capital Markets), as Vice President & Senior Research Analyst from 2007 to 2008, Thomas Weisel Partners LLC, as Vice President & Senior Research Analyst from 2003 to 2006, Janney Montgomery Scott LLC, as Research Analyst from 2014 to 2015, and SG Cowen Securities Corp., as Equity Research Associate in 2002. Mr. Lebowitz received his graduate degree from The Trustees of Columbia University in The City of New York, undergraduate degree from Brandeis University, and Masters Business Admin degree from The Leonard N Stern School of Business.
Follow on LinkedIn

David Lebowitz's Ratings History at Citigroup

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
9/3/2025Boost Price Target$60.15$84.00Buy
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
9/2/2025Boost Price Target$48.12$84.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
8/22/2025Boost Price Target$42.29$69.00Buy
Celldex Therapeutics, Inc. stock logo
CLDX
Celldex Therapeutics
8/20/2025Lower Price Target$21.36$48.00Buy
Schrodinger, Inc. stock logo
SDGR
Schrodinger
8/15/2025Downgrade$19.45$20.00Neutral
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
8/8/2025Reiterated Rating$191.49$290.00Buy
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
8/8/2025Lower Price Target$34.11$77.00Buy
Incyte Corporation stock logo
INCY
Incyte
7/30/2025Boost Price Target$78.05$103.00Buy
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
7/24/2025Boost Price Target$33.29$38.00Neutral
Cogent Biosciences, Inc. stock logo
COGT
Cogent Biosciences
7/18/2025Boost Price Target$12.46$22.00Buy
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
7/11/2025Boost Price Target$46.34$67.00Buy
Ascendis Pharma A/S stock logo
ASND
Ascendis Pharma A/S
7/11/2025Boost Price Target$175.67$243.00Buy
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
6/4/2025Upgrade$127.60$129.00Hold
Exelixis, Inc. stock logo
EXEL
Exelixis
5/15/2025Boost Price Target$47.21$56.00Buy
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
5/9/2025Lower Price Target$8.38$10.00Neutral
Intellia Therapeutics, Inc. stock logo
NTLA
Intellia Therapeutics
2/28/2025Boost Price Target$9.88$14.00Neutral
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2/21/2025Boost Price Target$36.88$49.00Buy
Ionis Pharmaceuticals, Inc. stock logo
IONS
Ionis Pharmaceuticals
2/20/2025Lower Price Target$32.57$64.00Buy
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
2/12/2025Boost Price Target$48.63$45.00Sell
Exelixis, Inc. stock logo
EXEL
Exelixis
2/12/2025Boost Price Target$33.18$45.00Buy
Incyte Corporation stock logo
INCY
Incyte
2/11/2025Lower Price Target$68.30$88.00Buy
Pliant Therapeutics, Inc. stock logo
PLRX
Pliant Therapeutics
2/10/2025Downgrade$7.79$4.00Neutral
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2/7/2025Initiated Coverage$46.17$86.00Buy
Viking Therapeutics, Inc. stock logo
VKTX
Viking Therapeutics
2/7/2025Initiated Coverage$31.46$38.00Neutral